Hepatitis B virus infection, hepatitis B vaccine, and hepatitis B immune globulin

被引:0
作者
Zimmerman, RK
Ruben, FL
Ahwesh, ER
机构
[1] UNIV PITTSBURGH,SCH MED,DEPT FAMILY MED & CLIN EPIDEMIOL,PITTSBURGH,PA 15260
[2] UNIV PITTSBURGH,SCH MED,DIV INFECT DIS,PITTSBURGH,PA 15260
关键词
hepatitis B virus; hepatitis B vaccines; immunization; public health; preventive services; sexually transmitted diseases; liver diseases; physicians; family;
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Hepatitis B virus (HBV) infection is a major health problem in the United States; in 1995, approximately 128,000 cases occurred. Transmission of HBV occurs primarily by blood exchange (ey, by shared needles during injection drug use) and by sexual contact, Persons infected early in life are much more likely to become chronically infected than those infected during adulthood: as many as 90% of infants infected perinatally develop chronic infection and up to 25% will die of HBV-related chronic liver disease as adults. Clinical signs of acute hepatitis occur in about 50% of infected adults but in only 5% of infected preschool-aged children. In the United States, hepatitis B vaccine is currently made by recombinant DNA technology using baker's yeast, Preexposure vaccination results in protective antibody levels in almost all infants and children (>95%) and healthy adults younger than 40 years of age (>90%). The most common adverse event following administration of hepatitis B vaccine is pain at the injection site, which occurs in 13% to 29% of adults and 3% to 9% of children. A comprehensive hepatitis B vaccination policy is now recommended that includes (1) routine infant vaccination; (2) catch-up vaccination of 11- to 12-year-olds who were not previously vaccinated; (3) catch-up vaccination of young children at high risk for infection; (4) vaccination of adolescents and adults based on lifestyle or environmental, medical, and occupational situations that place them at risk; and (5) prevention of perinatal HBV infection.
引用
收藏
页码:295 / 315
页数:23
相关论文
共 45 条
[1]   GENETIC PREDICTION OF NONRESPONSE TO HEPATITIS-B VACCINE [J].
ALPER, CA ;
KRUSKALL, MS ;
MARCUSBAGLEY, D ;
CRAVEN, DE ;
KATZ, AJ ;
BRINK, SJ ;
DIENSTAG, JL ;
AWDEH, Z ;
YUNIS, EJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (11) :708-712
[2]   IMPORTANCE OF HETEROSEXUAL ACTIVITY IN THE TRANSMISSION OF HEPATITIS-B AND NON-A, NON-B HEPATITIS [J].
ALTER, MJ ;
COLEMAN, PJ ;
ALEXANDER, WJ ;
KRAMER, E ;
MILLER, JK ;
MANDEL, E ;
HADLER, SC ;
MARGOLIS, HS .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1989, 262 (09) :1201-1205
[3]   THE CHANGING EPIDEMIOLOGY OF HEPATITIS-B IN THE UNITED-STATES - NEED FOR ALTERNATIVE VACCINATION STRATEGIES [J].
ALTER, MJ ;
HADLER, SC ;
MARGOLIS, HS ;
ALEXANDER, WJ ;
HU, PY ;
JUDSON, FN ;
MARES, A ;
MILLER, JK ;
MOYER, LA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 263 (09) :1218-1222
[4]  
[Anonymous], 1996, MMWR Recomm Rep, V45, P1
[5]  
[Anonymous], 1996, GUID CLIN PREV SERV
[6]  
AVERHOFF F, 1994, 34 ICAAC OCT 4 7 199
[7]   A REAPPRAISAL OF HEPATITIS-B VIRUS VACCINATION STRATEGIES USING COST-EFFECTIVENESS ANALYSIS [J].
BLOOM, BS ;
HILLMAN, AL ;
FENDRICK, AM ;
SCHWARTZ, JS .
ANNALS OF INTERNAL MEDICINE, 1993, 118 (04) :298-306
[8]  
*CDC, 1990, MMWR-MORBID MORTAL W, V39, P619
[9]  
*CDC, 1993, MMWR-MORBID MORTAL W, V42, P707
[10]  
*CDC, 1991, MMWR-MORBID MORTAL W, V40, P1